To evaluate the morbidity and mortality of Candida fungemia and to assess the efficacy of low- vs high-dose amphotericin B and fluconazole vs amphotericin B in patients with candidemia.
Multicenter, prospective, observational study of 427 consecutive patients with candidemia.
The mortality rate for patients with candidemia was 34%. The mortality rate for patients with catheter-related candidemia in whom the catheters were retained was significantly higher than that of patients in whom the catheters were removed (41% vs 21%, P<.001). We found no overall difference in mortality in patients treated with low-dose (total amphotericin B dose of ≤500 mg) (13%) vs high-dose amphotericin B (total amphotericin B dose of >500 mg) (15%), but the group treated with a low dose had fewer side effects (40%) than those treated with a high dose (55%) (P=.03). Fluconazole was as efficacious as amphotericin B in the therapy of candidemia, even when stratified by risk factors for mortality. Fewer side effects were seen with fluconazole (12%) compared with amphotericin B (44%) (P<.001).
In selected patients with candidemia, low-dose amphotericin B was as efficacious as high-dose amphotericin B. Based on other studies and ours, fluconazole seems to be an alternative therapeutic option to amphotericin B in selected patients.(Arch Intern Med. 1995;155:2429-2435)
Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic Approaches in Patients With Candidemia: Evaluation in a Multicenter, Prospective, Observational Study. Arch Intern Med. 1995;155(22):2429–2435. doi:10.1001/archinte.1995.00430220087009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: